drugset / Trial / NCT06577961
Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients
Phase 1/2
Not yet recruiting
37 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the efficacy and safety of vorolanib combined with cadonilimab in the treatment of untreated advanced RCC patients.
Timeline
- Start
- 2024-08-31
- Primary completion
- 2027-08-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM082 | Unknown | 200 mg | — |
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | — |